- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02740218
A Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology Practice (APPRECIATE)
March 1, 2024 updated by: Amgen
APPRECIATE (Apremilast Clinical Treatment Experience in Psoriasis): A Multi-center, Retrospective Observational Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology Practice
This is a retrospective, multi-center observational cohort study.
This study will be implemented first in Germany (approximately 50 sites), the United Kingdom (approximately 20 sites) and Sweden (approximately 25 sites), followed by a selected number of countries in Europe, depending on apremilast local availability.
The design of this apremilast retrospective study aims to provide clinical information regarding the treatment initiation and outcomes in psoriasis patients when prescribed apremilast in real world settings.
In addition, this study is aiming at capturing physicians' and patients' treatment goals when initiating apremilast and whether these goals are achieved following apremilast use.
This study is primarily descriptive in nature, and no a priori hypotheses are specified.
Patients must voluntarily sign an informed consent form, be 18 or over, have been diagnosed with plaque psoriasis and have been treated with apremilast during the previous 5-7 months to participate in this study.
They must not be involved in any other clinical study involving apremilast.
Study Overview
Study Type
Observational
Enrollment (Actual)
610
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Graz, Austria, 8036
- Medizinische Universität Graz
-
Großwarasdorf, Austria, 7304
- Praxis Dr. Wolfgang Fuchs
-
Klagenfurt, Austria, 9020
- Praxis Dr. Schicher
-
Landeck, Austria, 6500
- Praxis Dr. Wilhelm
-
Linz, Austria, 4021
- Kepler Universitätsklinikum
-
Linz, Austria, 4040
- Praxis Dr. Dunst-Huemer
-
Wels, Austria, 4600
- Klinikum Wels-Grieskirchen GmbH
-
Wien, Austria, 1090
- Medizinische Universität Wien
-
Wien, Austria, 1130
- Krankenhaus Hietzing
-
Wien, Austria, 1030
- Krankenanstalt Rudolfstiftung
-
Wien, Austria, 1100
- Praxis Dr. Göttfried
-
Wien, Austria, 1100
- Praxis Dr. Holub-Hoberger
-
Wien, Austria, 1170
- Praxis Dr. Nordberg
-
Wien, Austria, 1190
- Praxis Dr. Menzinger
-
Wien, Austria, 1190
- Praxis Dr. Sator
-
Wien, Austria, 1200
- Praxis Dr. Perl-Convalexius
-
Wiener Neustadt, Austria, 2700
- Landesklinikum Wiener Neustadt
-
-
-
-
-
Osijek, Croatia, 31 000
- Klinički bolnički centar Osijek Zavod za dermatologiju i venerologiju
-
Rijeka, Croatia, 51000
- Klinički bolnički centar Rijeka Klinika za dermatovenerologiju
-
Split, Croatia, 21 000
- Klinički bolnički centar Split Klinika za kožne i spolne bolesti
-
Zagreb, Croatia, 10 000
- Klinički bolnički centar Sestre milosrdnice Klinika za kožne i spolne bolest
-
Zagreb, Croatia, 10 000
- Klinički bolnički centar Zagreb Klinika za dermatovenerologiju
-
-
-
-
-
Jihlava, Czechia, 586 33
- Nemocnice Jihlava příspěvková organizace
-
Plzen, Czechia, 301 00
- FN Plzen Bory Dermatovenerologické oddělení
-
-
Novy Hradec Králové
-
Hradec Králové, Novy Hradec Králové, Czechia, 500 05
- Fakultní nemocnice Hradec Králové Klinika nemocí kožních a pohlavních
-
-
Pardubice IV
-
Pardubice, Pardubice IV, Czechia, 530 03
- Nemocnice Pardubického kraje
-
-
Praha 1
-
Praha, Praha 1, Czechia, 110 00
- Sanatorium profesora Arenberger
-
-
Praha 2
-
Praha, Praha 2, Czechia, 128 08
- Vseobecna fakultni nemocnice v Praze
-
-
Praha 5
-
Praha, Praha 5, Czechia, 150 06
- Fakultni nemocnice v Motole
-
-
-
-
-
Aachen, Germany, 52062
- Praxis Dr. Harst
-
Aachen, Germany, 52066
- Praxis Dr. Wagner-Schiffler
-
Ampfing, Germany, 84539
- Praxis Dr. Dietz
-
Andernach, Germany, 56626
- Praxis Dr. Bell
-
Augsburg, Germany, 86179
- Licca Clinical Research Institute
-
Blaustein, Germany, 89134
- Gefäß- und Hautzentrum Blaustein
-
Bochum, Germany, 44791
- St. Josef und St. Elisabeth Hospital gGmbH
-
Bonn, Germany, 53127
- Rheinische Friedrich-Wilhelms-Universität Bonn
-
Brühl, Germany, 50321
- Praxis Dr. Jordan
-
Buxtehude, Germany, 21614
- Elbe Klinikum Buxtehude
-
Dachau, Germany, 85221
- Praxis Dr. Schneider
-
Delmenhorst, Germany, 27753
- Praxis Dr. Thelen
-
Dortmund, Germany, 44137
- Klinikum Dortmund
-
Dresden, Germany, 01217
- Praxis Dr. Scheibner
-
Düren, Germany, 52349
- Praxis Dr. Korge
-
Eltville, Germany, 65343
- Praxis für Dermatologie und Venerologie, Allergologie
-
Endingen, Germany, 79346
- Praxis Dr. Schurhammer-Fuhrmann
-
Erlangen, Germany, 91054
- Uniklinikum Erlangen
-
Euskirchen, Germany, 53879
- Praxis Dr. Huerkamp
-
Euskirchen, Germany, 53879
- Praxis Dr. Swirski
-
Frankfurt, Germany, 60590
- Universitätsklinikum Frankfurt
-
Freiberg, Germany, 09599
- Praxis Dr. Kämmerer
-
Freising, Germany, 85354
- Praxis Dr. Kurzen
-
Gelsenkirchen, Germany, 45883
- GP Dr. Rotterdam & Kollegen
-
Gilching, Germany, 82205
- Praxis Dr. med W. Klövekorn, Dr. med. A. Tepe, Dr. med. O. Wilde
-
Hamburg, Germany, 20246
- Universitätsklinikum Hamburg-Eppendorf
-
Kusel, Germany, 66869
- Praxis Dr. Schmidt
-
Malchow, Germany, 17231
- Praxis Birgit Zimmermann
-
Mechernich, Germany, 53894
- Praxis Dr. Piontek
-
Memmingen, Germany, 87700
- Dermatologische Praxis Dr. med. Schwinn
-
Memmingen, Germany, 87700
- Praxis Büchler
-
Mühldorf, Germany, 84453
- Praxis Dr. Antal
-
Mühlheim, Germany, 56218
- Praxis Dr. Cords
-
München, Germany, 80331
- Praxis Dr. Liebich
-
München, Germany, 80802
- Technische Universität München
-
Regensburg, Germany, 93053
- Universitätsklinikum Regensburg
-
Rosenheim, Germany, 83022
- Praxis Dr. Prell
-
Rostock, Germany, 18055
- Praxis Dr. Blank
-
Rostock, Germany, 18059
- Praxis Dr. Hoene
-
Sankt Ingbert, Germany, 66386
- Praxis Dr. Schenkelberger
-
Stolberg, Germany, 52222
- Praxis Dr. Neisius
-
Straubing, Germany, 94315
- Praxis Dr. Steinborn
-
Tübingen, Germany, 72076
- Universitätsklinikum Tübingen
-
Vilshofen, Germany, 94474
- Gemeinschaftspraxis Dr. Christian Fischer, Florian Kreuziger
-
Wasserburg am Inn, Germany, 83512
- Praxis Dr. Dehmel
-
Wesseling, Germany, 50389
- Praxis Dr. Schmeel
-
Wildau, Germany, 15745
- Praxis Dr. Buttgereit
-
Wittlich, Germany, 54516
- Praxis Dr. Süß
-
-
Westerwald
-
Selters, Westerwald, Germany, 56242
- Company for Medical Study & Service
-
-
-
-
-
Dublin 7, Ireland
- Mater Misericordiae University Hospital
-
Galway, Ireland, H91 YR71
- University Hospital Galway
-
-
County Kerry
-
Tralee, County Kerry, Ireland
- Bon Secours Hospital
-
-
-
-
-
Maribor, Slovenia, 2000
- Uniiverzitetni klinični center Maribor Oddelek za kožne in spolne bolezni
-
-
-
-
-
Benalmádena, Spain, 29631
- Vithas Xanit Iinternational Hospital
-
Granada, Spain, 18016
- Hospital Universitario San Cecilio (PTS)
-
Malaga, Spain, 29010
- Hospital Virgen de la Victoria
-
-
Madrid
-
Alcorcón, Madrid, Spain, 28922
- Hospital Fundacion Alcorcon, Madrid
-
-
-
-
-
Eskilstuna, Sweden, 631 88
- Hudkliniken Mälarsjukhuset
-
Göteborg, Sweden, 413 45
- Hudkliniken SU/ Sahlgrenska
-
Karlskoga, Sweden, 69181
- Hudmottagningen Karlskoga Lasarett
-
Lindesberg, Sweden, 711 35
- Hudmottagningen Lindesbergs Lasarett
-
Lund, Sweden, 222 21
- Capio Citykliniken Lund
-
Malmö, Sweden, 211 18
- Diagnostiskt Centrum Hud Malmö
-
Malmö, Sweden, 214 28
- SUS Malmö Hudkliniken
-
Norrköping, Sweden, 601 82
- Hudkliniken Vrinnevisjukhuset Norrköping
-
Stockholm, Sweden, 111 37
- Diagnostiskt Centrum Hud Stockholm
-
Stockholm, Sweden, 113 22
- Cutisgruppen/Stockholm Hud
-
Stockholm, Sweden, 118 83
- Hudkliniken SÖS
-
Stockholm, Sweden, 133 30
- Hudcentrum Hagastaden
-
Stockholm, Sweden, 17176
- Karolinska Psoriasis Center
-
Stockholm, Sweden, 182 88
- Hudkliniken Danderyds Sjukhus
-
Trelleborg, Sweden, 231 85
- Hudmottagningen Trelleborg
-
Västervik, Sweden, 593 33
- Hudmottagningen Västervik
-
-
-
-
-
Basel, Switzerland, 4051
- Dermatologie Aesche
-
Basel, Switzerland, 4052
- Somamedica
-
Bellinzona, Switzerland, 6500
- Ospedale Bellinzona e Valli EOC
-
Bern, Switzerland, 3010
- Insel Gruppe AG
-
Genève, Switzerland, 1201
- Clinique dermatologie du Seujet
-
Herzogenbuchsee, Switzerland, 3360
- Hautarzt Oberaargau AG
-
Lausanne, Switzerland, 1011
- Centre Hospitalier Universitaire Vaudois (CHUV)
-
Lugano, Switzerland, 6900
- Studio medico Dr. Pelloni
-
Martigny, Switzerland, 1920
- Practice Dr. Niklaus
-
Olten, Switzerland, 4600
- Pallas Klinik Olten
-
St. Gallen, Switzerland, 9000
- Haut und Laserzentrum Dr. Zuder
-
St. Gallen, Switzerland, 9000
- Praxis Dr. med. Christian Schuster
-
Uster, Switzerland, 8610
- Haut und Allergiezentrum Brunnehof
-
Weinfelden, Switzerland, 8570
- Dr. Tomi Haut- und Laserzentrum
-
Winterthur, Switzerland, 8400
- Hautpraxis Dermateam
-
Wohlen, Switzerland, 5610
- Praxisgemeinschaft Bünz AG
-
Zug, Switzerland, 6300
- Zug Hautarzt
-
Zürich, Switzerland, 8091
- Universitatsspital Zurich
-
-
-
-
-
Aberdeen, United Kingdom, AB25 2ZB
- Aberdeen Royal Infirmary
-
Bradford, United Kingdom, BD9 6RJ
- Bradford Teaching Hospitals NHS
-
Bury St Edmunds, United Kingdom, IP33 2QZ
- West Suffolk NHS Foundation
-
Canterbury, United Kingdom, CT1 3NG
- East Kent & Canterbury Hospital
-
Dumfries, United Kingdom, DG1 4AP
- NHS Dumfries and Galloway
-
Exeter, United Kingdom, EX2 5DW
- Royal Devon & Exeter NHS Foundation Trust
-
Isleworth, United Kingdom, TW7 6AF
- West Middlesex University Hospital
-
Leeds, United Kingdom, LS9 7TF
- Chapel Allerton Hospital
-
London, United Kingdom, SE1 9RT
- Guy's and St Thomas's NHS Foundation Trust
-
London, United Kingdom, SW10 9NH
- Chelsea & Westminster NHS Foundation Trust
-
Newcastle upon Tyne, United Kingdom, NE7 7DN
- Royal Victoria Infirmary
-
Salford, United Kingdom, M6 8HD
- University of Manchester
-
Warwick, United Kingdom, CV34 5BW
- Warwick Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patient charts will be selected for data abstraction by participating dermatologists and will be determined eligible for study enrollment based on the inclusion criteria.
All consecutive adult psoriasis patients who can be contacted 6 months (+/- 1 month) following initiation of treatment with apremilast will be approached for entry to minimize bias in patient selection.
All eligible patients will be included in consecutive order regarding the date of the signed Informed Consent.
Description
Inclusion Criteria:
- Must have understood and voluntarily signed the Informed Consent Form (ICF).
- Age ≥ 18 years at the time of signing the ICF.
- Diagnosed with plaque psoriasis.
- Initiated treatment with apremilast 6 months (+/- 1 month) previously (patients may or may not have completed 6 months of apremilast treatment)
Exclusion Criteria:
- Refusal to participate in this study or current participation in the treatment phase of an interventional clinical trial.
- Started apremilast as part of a clinical trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Psoriasis patients
Single cohort of psoriasis patients treated with OTEZLA (apremilast)
|
Patients will be asked to complete a questionnaire regarding their expectations, experience and satisfaction in taking OTEZLA (apremilast) treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Patient Benefit Index (PBI) outcome score
Time Frame: Up to approximately 7 months
|
Is a questionnaire regarding patient expectations and benefit of psoriasis treatment with apremilast, eg, effect on specific symptoms.
|
Up to approximately 7 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment Satisfaction Questionnaire for Medication (TSQM) outcome score
Time Frame: Up to approximately 7 months
|
The TSQM-9 is a self-administrated instrument to understand a subject's satisfaction on the current therapy
|
Up to approximately 7 months
|
Percentage of patients achieving PASI75
Time Frame: Up to approximately 7 months
|
PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 16.
The improvement in PASI score was used as a measure of efficacy.
The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions.
PASI scores range from 0 to 72, with higher scores reflecting greater disease severity.
Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs.
Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).
The PASI score was set to missing if any severity score or degree of involvement is missing.
|
Up to approximately 7 months
|
Percentages of patients achieving PASI50
Time Frame: Up to approximately 7 months
|
PASI score is based on an assessment of erythema (reddening), induration (plaque thickness), desquamation (scaling), and the percent area affected as observed on the day of examination.
|
Up to approximately 7 months
|
Mean change in Dermatology Life Quality Index (DLQI)
Time Frame: Up to approximately 7 months
|
DLQI is a simple, compact, and practical questionnaire for use in a dermatology clinical setting to assess limitations related to the impact of skin disease.
The instrument contains ten items dealing with the participant's skin.
With the exception of Item Number 7, the participant responds on a four-point scale, ranging from "Very Much" (score 3) to "Not at All" or "Not relevant" (score 0).
Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No, scores 3 or 0 respectively), and if "No," then the participant is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being "A lot," "A little," or "Not at all" (scores 2, 1, or 0 respectively).
The DLQI total score is derived by summing all item scores, which has a possible range of 0 to 30, with 30 corresponding to the worst quality of life, and 0 corresponding to the best.
|
Up to approximately 7 months
|
Percentages of patients achieving ≥5 point improvement in DLQI
Time Frame: Up to approximately 7 months
|
DLQI is a simple, compact, and practical questionnaire for use in a dermatology clinical setting to assess limitations related to the impact of skin disease.
The instrument contains ten items dealing with the participant's skin.
With the exception of Item Number 7, the participant responds on a four-point scale, ranging from "Very Much" (score 3) to "Not at All" or "Not relevant" (score 0).
Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No, scores 3 or 0 respectively), and if "No," then the participant is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being "A lot," "A little," or "Not at all" (scores 2, 1, or 0 respectively).
The DLQI total score is derived by summing all item scores, which has a possible range of 0 to 30, with 30 corresponding to the worst quality of life, and 0 corresponding to the best.
|
Up to approximately 7 months
|
Percentages of patients achieving PASI50 plus ≥5 point improvement in DLQI
Time Frame: Up to approximately 7 months
|
PASI score is based on an assessment of erythema (reddening), induration (plaque thickness), desquamation (scaling), and the percent area affected as observed on the day of examination. DLQI is a simple, compact, and practical questionnaire for use in a dermatology clinical setting to assess limitations related to the impact of skin disease |
Up to approximately 7 months
|
Mean change in Body Surface Area (BSA)
Time Frame: Up to approximately 7 months
|
BSA was a measurement of involved skin.
The overall BSA affected by psoriasis was estimated based on the palm area of the participant's hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total body surface area.
|
Up to approximately 7 months
|
Mean change in PGA
Time Frame: Up to approximately 7 months
|
The PGA is a 5-point scale ranging from 0 (clear) to 4 (severe), incorporating an assessment of the severity of the 3 primary signs of the disease: erythema, scaling and plaque elevation.
When making the assessment of overall severity, the assessor factors in areas that have already cleared (ie, have scores of 0) and not just remaining lesions for severity, ie, the severity of each sign was to be averaged across all areas of involvement, including cleared lesions
|
Up to approximately 7 months
|
Percentage of patients achieving PGA 0/1 (clear/almost clear)
Time Frame: Up to approximately 7 months
|
The PGA is a 5-point scale ranging from 0 (clear) to 4 (severe), incorporating an assessment of the severity of the 3 primary signs of the disease: erythema, scaling and plaque elevation.
When making the assessment of overall severity, the assessor factors in areas that have already cleared (ie, have scores of 0) and not just remaining lesions for severity, ie, the severity of each sign was to be averaged across all areas of involvement, including cleared lesions
|
Up to approximately 7 months
|
Adverse Events (AEs)
Time Frame: Up to approximately 7 months
|
Number of patients with adverse events
|
Up to approximately 7 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: MD, Amgen
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Pedro Herranza, Lidia Trasobaresb, Almudena Mateuc, Esperanza Martínezd, Ricardo Ruiz-Villaverdee, Ofelia Baniandrésf, Javier Mataixg, Natalia Jiménez-Gómezh, Marta Serrai, Diana Patricia Ruiz Genaoj, Noelia Riverak, Jesús Tercedor-Sánchezl, Carmen Garciam, Myriam Cordeyn, Enrique Herrera-Acostao. Characterization and outcomes of patients treated with apremilast in the Spanish routine clinical practice: Results from the APPRECIATE study. Actas Dermosifiliogr.
- Cetkovska P, Dediol I, Sola M, Kojanova M, Trcko K, Carija A, Ceovic R, Ledic-Drvar D, Kastelan M, Hrabar A, Missoup MC, Mamun K. Apremilast Use in Severe Psoriasis: Real-World Data from Central and Eastern Europe. Adv Ther. 2023 Apr;40(4):1787-1802. doi: 10.1007/s12325-023-02468-3. Epub 2023 Mar 2.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 30, 2016
Primary Completion (Actual)
October 27, 2021
Study Completion (Actual)
October 27, 2021
Study Registration Dates
First Submitted
April 12, 2016
First Submitted That Met QC Criteria
April 12, 2016
First Posted (Estimated)
April 15, 2016
Study Record Updates
Last Update Posted (Actual)
March 4, 2024
Last Update Submitted That Met QC Criteria
March 1, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CC-10004-PSOR-013
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriasis
-
ProgenaBiomeRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Face | Psoriasis Nail | Psoriasis Diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis Annularis | Psoriasis Genital | Psoriasis GeographicaUnited States
-
Clin4allRecruitingPsoriasis of Scalp | Psoriasis Nail | Psoriasis Palmaris | Psoriasis Genital | Psoriasis PlantarisFrance
-
Innovaderm Research Inc.CompletedScalp Psoriasis | Pustular Palmo-plantar Psoriasis | Non-pustular Palmo-plantar Psoriasis | Elbow Psoriasis | Lower Leg PsoriasisCanada
-
Centre of Evidence of the French Society of DermatologyRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Palmaris | Psoriatic Erythroderma | Psoriatic Nail | Psoriasis Guttate | Psoriasis Inverse | Psoriasis PustularFrance
-
UCB Biopharma S.P.R.L.CompletedModerate to Severe Psoriasis | Generalized Pustular Psoriasis and Erythrodermic PsoriasisJapan
-
AmgenCompletedPsoriasis-Type Psoriasis | Plaque-Type PsoriasisUnited States
-
Janssen Pharmaceutical K.K.RecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Eli Lilly and CompanyCompletedGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
TakedaRecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Herlev and Gentofte HospitalRecruitingMyocardial Infarction | Myocardial Ischemia | Heart Diseases | Cardiovascular Diseases | Heart Failure | Stroke | Psoriasis | Heart Failure, Diastolic | Psoriasis Vulgaris | Cardiovascular Risk Factor | Heart Failure, Systolic | Left Ventricular Dysfunction | Psoriasis Universalis | Psoriasis Face | Psoriasis Diffusa | Psoriasis... and other conditionsDenmark
Clinical Trials on Patient questionnaire
-
Minneapolis Heart Institute FoundationRecruitingAortic Valve Stenosis | Disparities in Treatment of Aortic Valve StenosisUnited States
-
Assistance Publique Hopitaux De MarseilleCompleted
-
University Hospital, Basel, SwitzerlandCompleted
-
Assistance Publique - Hôpitaux de ParisWithdrawnChronic Otitis MediaFrance
-
Hôpital NOVOCompletedPregnancy RelatedFrance
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Roswell Park Cancer InstituteNot yet recruitingBreast Carcinoma | Breast Ductal Carcinoma in Situ
-
Weill Medical College of Cornell UniversityPatient-Centered Outcomes Research InstituteEnrolling by invitationProstate CancerUnited States
-
Lawson Health Research InstituteCompleted
-
University of ManitobaUnknownComplete EdentulismCanada